SPECIAL ANNOUNCEMENT: World Kidney Day: An idea whose time has come  by Collins, Allan J. et al.
Kidney International (2006) 69       781
editorialhttp://www.kidney-international.org
© 2006 International Society of Nephrology
SPECIAL ANNOUNCEMENT
World Kidney Day: An Idea Whose Time 
Has Come
Kidney International (2006) 69, 781–782. doi:10.1038/sj.ki.5000250
Developed by the International Federation of Kidney Foundations (IFKF) and the International 
Society of Nephrology (ISN), Committee for World Kidney Day.
T
he world needs a kidney day to draw 
global attention to the increasing global 
pandemic of kidney and associated car-
diovascular disease. Th erefore, the Inter-
national Society of Nephrology (ISN) and the 
International Federation of Kidney Foundations 
(IFKF) jointly are proposing that a World Kid-
ney Day be established on the second Th ursday in 
March each year. It will be launched on Th ursday, 
March 9, 2006, and fully inaugurated on Th urs-
day, March 8, 2007. Th e aim is to broadcast the 
message about kidney disease to government 
health offi  cials, general physicians, allied health 
professionals, individuals, and families.
Worldwide, most individuals with chronic kid-
ney disease or hypertension are not diagnosed 
until long aft er the illness has developed. More-
over, when they are diagnosed, they too oft en are 
treated suboptimally or not at all. In most parts of 
the world, once end-stage kidney failure occurs, 
patients do not have access to maintenance hemo-
dialysis treatment or kidney transplantation and 
simply die.
For these reasons, it is time to speak up and 
to speak clearly, because the extent and severity 
of kidney disease has not been appreciated for a 
long time. Moreover, the availability of easy meth-
ods for early detection and the proven benefi ts of 
preventive therapy are not widely known. A day 
when attention to kidney disease is brought to the 
world’s population is timely. It could also serve 
as a day to express appreciation for the billions 
of dollars of support for a disease that currently 
requires high-technology treatment.
Kidney disease is a signifi cant interactive dis-
ease in patients with diabetes, hypertension, and 
cardiovascular disease with major morbidity 
and mortality consequences and high costs to 
the healthcare system. Moreover, patients with 
chronic kidney disease have a marked increase 
in risk for developing cardiovascular disease. 
However, as kidney disease is easy to detect with 
simple, routinely available tests (serum creatinine 
and urine albumin), both chronic kidney disease 
and the potential associated cardiovascular com-
plications can be prevented and eff ectively treated 
with intensive blood pressure control, glucose 
control in diabetic patients, lipid-lowering medi-
cations, and the use of kidney-protective medi-
cations such as angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers. Pre-
vention and slowing the progression of chronic 
kidney disease are the only rational public health 
approaches to addressing the ever-increasing 
numbers of patients with end-stage renal disease 
and reducing the associated cardiovascular risk 
in these patients.
Th e decision makers of public health and bio-
medical science view kidney disease as infre-
quent and costly. However, newer information 
and scientific evidence have given persuasive 
proof that there is more kidney disease than had 
been thought. Developed countries worldwide 
treat more than 1,000,000 individuals yearly, and 
as many as 250,000 new cases each year.1 In the 
United States and Th e Netherlands, it is estimated 
that 6.5% to 10% of the general population suff er 
from some degree of kidney disease and are there-
fore at increased risk of preventable cardiovas-
cular disease and renal failure. Kidney disease is 
increasing rapidly in the developing world, along 
with the prevalence of diabetes and hyperten-
sion. However, since dialysis costs can average 
$65,000 per year and transplantation can cost up 
to $40,000, neither is available to the vast majority 
of people living outside the developed world.
Some emerging evidence points out that end-
stage renal disease rates are slowing and, in fact, 
decreasing in certain populations. Th ese trends 
are consistent with increased use of angiotensin-
converting enzyme inhibitors and angiotensin 
receptor blockers and with better blood pressure 
control and better control of the blood sugar in 
diabetic patients. Yet, worldwide there is a pan-
demic of type II diabetes and associated metabolic 
syndrome, so there continues to be substantial 
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room for improvement. Th e number of patients with type II dia-
betes worldwide will increase from 154 to 360 million by 2030, 
with at least 40% of these patients developing chronic kidney dis-
ease with its associated increased cardiovascular risk, and more 
than 10% developing end-stage renal disease unless aggressive 
measures of early detection and intervention programs are initi-
ated. Intensifi ed eff orts should yield further reductions in end-
stage renal disease rates, at least in the short run, with more data 
needed to determine if decreases are sustainable.2
Th e public health mandate is clear for governments: detection 
and prevention are the most cost-eff ective methods to address 
chronic kidney disease and its impact on diabetes and cardio-
vascular disease. Targets have been defi ned for blood pressure. 
Early referral to nephrologists for more complete assessment of 
interventions, as well as other preventive care measures includ-
ing infl uenza vaccinations and pneumococcal vaccinations, are 
needed to reduce hospitalization rates for infectious complications 
that are four times higher in patients suff ering from chronic kid-
ney disease.3 Detection eff orts center on accurate measurements 
of serum creatinine and albumin in the urine in the estimating 
equation to assess the level of kidney disease.4 Strategies to stand-
ardize these measurements should become a global priority.
Patients who start dialysis or receive kidney transplants experi-
ence the most direct consequences of kidney disease; early detec-
tion and intervention could have saved the ravages of kidney 
failure. Because of genetic linkages between diabetes and hyper-
tension, the leading causes of kidney failure, kidney disease runs 
in families. Genetic diseases, such as polycystic kidney disease 
among others, and genetic abnormalities also run in families. In 
some developing countries malaria, human immunodefi ciency 
virus/acquired immunodefi ciency syndrome, tuberculosis, and 
childhood infections such as diarrheal diseases are signifi cant 
causes of kidney disease. Awareness about how to deal with acute 
renal failure, which is reversible, could reduce both unnecessary 
mortality and morbidity. In some countries there is a lack of basic 
knowledge about diagnosing and treating kidney stones. A World 
Kidney Day could play an important role in educating physicians 
and the public about all these issues.
Several international medical organizations have established 
eff ective special days to draw attention to specifi c diseases. Th e 
primary purposes of these days are to bring the specifi c disease 
to the forefront as an issue for personal/family health and to 
provide information about early symptoms and the simple clini-
cal and laboratory tests available for diagnosis. ISN and IFKF 
have decided it is time for our organizations to follow suit by 
establishing a World Kidney Day—one additional instrument to 
help achieve better understanding of kidney disease. Th e hope 
is to enlist every national kidney society and every local kidney 
foundation worldwide to join with us. We believe World Kidney 
Day will be recognized by world bodies as other special days 
have been.
Media attention, interviews with aff ected patients, commu-
nity awareness programs, and professional education eff orts 
all create awareness that aff ect public attitudes and behaviors 
toward prevention and early treatment of the specifi c disease 
being profi led. Kidney disease, with its devastating conse-
quences when left  untreated, is one that would benefi t from 
this type of public exposure.
An initial World Kidney Day on March 9, 2006, will prepare 
the way for a full inauguration on March 8, 2007. It will be vital 
that all nephrologists become involved. It is our hope that World 
Kidney Day will be important not only to North America and 
Europe, but also in all developing countries, in places as diverse 
as Myanmar, Yemen, Angola, and Bolivia. Th e challenge is great, 
but the promise is even greater: that by working together we can 
achieve a major reduction in the global burden of kidney and 
cardiovascular disease. We must act, and act now.
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